TCA
MDGL icon

Transcend Capital Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Transcend Capital Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-673
Closed -$309K – 733
2025
Q3 		$309K Buy
+673
New +$251K 0.02% 523

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Transcend Capital Advisors's MDGL Position: Q4 2025 in Review

Transcend Capital Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 673 shares — an estimated $309K sold.

Transcend Capital Advisors first reported a position in MDGL in Q3 2025 and held it in 1 quarter. The position peaked at $309K in Q3 2025. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

  • Transcend Capital Advisors reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Transcend Capital Advisors sold 673 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $309K.
  • Transcend Capital Advisors first reported a position in Madrigal Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Transcend Capital Advisors's Madrigal Pharmaceuticals position peaked at $309K in Q3 2025.
  • 387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on Transcend Capital Advisors's 13F filing for Q4 2025, filed 23 Jan 2026.